Abstract:Objectives: The objectives of this study were to examine the degree to which long-term care providers are compliant with product labeling regarding administration of alendronate in patients with renal insufficiency and presence of, or predisposition to, upper gastrointestinal disorders; and to observe differences, if any, in prescribing patterns between alendronate and calcitonin-salmon nasal spray in skilled nursing facilities. Study design: We studied retrospectively analyzed patient charts, including medication histories and laboratory data. Setting: Our study comprised 134 skilled nursing facilities from 21 states. Participants: We studied postmenopausal women, age > or =65 years, receiving either alendronate or calcitonin-salmon nasal spray for a minimum of 2 weeks. Measurements: Consultant pharmacists reviewed resident charts submitted the following data for each resident: 2-week history of alendronate or calcitonin use, 2-week history of H2 receptor antagonist or proton pump inhibitor use, most recently documented serum creatinine, actual body weight, and date of birth. Results: Of 905 subjects in the analysis, 38.5% (n = 348) did not have documentation of serum creatinine. Of the 267 alendronate patients for whom creatinine clearance could be calculated, more than half had renal insufficiencies of creatinine clearance <35 mL/min/1.73 m(2) (51.3%, n = 137). In addition, despite widespread information regarding caution in using alendronate in patients with upper gastrointestinal disorders, we found that 33.9% (n = 151) of all alendronate patients were concurrently receiving either H2 receptor antagonists or proton pump inhibitors. Although similar results were observed in the residents taking calcitonin, that agent has no precautions regarding its use in the renally impaired or in patients with gastrointestinal disorders. Conclusion: Data from this study indicate that long-term care clinicians might not be adequately differentiating patient profiles and safety criteria when initiating residents on osteoporosis pharmacotherapy, as evidenced by similar prescribing trends in both the alendronate and calcitonin groups. Given its package insert's statements regarding use of alendronate in the renally compromised, results from the alendronate group were particularly problematic as a result of the large number of residents with either insufficient renal function or undocumented serum creatinine. These data demonstrate that osteoporosis could be a disease state that should be more closely analyzed through drug utilization reviews and represent yet another opportunity for improved collaboration between medical directors and consultant pharmacists.

Assessment of adherence to treatment with low-dose alendronate sodium combined with encouraging education in patients with osteoporosis

The effects of Alendronate on bone mineral density in RA patients with osteoporosis or osteopenia

Effects of bi-weekly oral alendronate sodium on medication adherence in patients with osteoporosis

The Effects of Health Education and Comprehensive Lifestyle Modification on Postmenopausal Osteoporosis Women Treatment with Alendronate Sodium

A randomized, double-blind, placebo-controlled study to evaluate the effects of alendronate on bone mineral density and bone remodelling in perimenopausal women with low bone mineral density

Clinical analysis of alendronate sodium treatment for diabetes patients with osteoporosis

Comparison of Clinical Efficacy and Safety Between Denosumab and Alendronate in Postmenopausal Women with Osteoporosis: a Meta-Analysis

Comparison of Several Early Drug Interventions in Postmenopausal Women with Osteopenia

Analysis of osteoporosis treatment initiation rate and adherence in elderly osteoporosis patients with hip fracture

Effect of alendronate on bone turnover biomarkers in postmenopausal osteoporosis

The Effect of Effervescent and Buffered Alendronate Compared to Conventional Alendronate on Markers of Bone Turnover: A Randomized Non-inferiority Trial

Study of Ibandronate and Alendronate Treatment for Postmenopausal Osteoporosis

Alendronate sodium/vitamin D3 combination tablet versus calcitriol for osteoporosis in Chinese postmenopausal women: a 6-month, randomized, open-label, active-comparator-controlled study with a 6-month extension

Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment: Exploratory results from a phase 3, randomized, controlled trial on postmenopausal osteoporotic women in China.

The Effect of Education Intervention on Osteoporotic Fracture and Bone Mineral Density in Elderly Women With Osteoporosis: A Randomized Controlled Trial.

An opportunity for medication risk reduction, healthcare provider collaboration, and improved patient care: a retrospective analysis of osteoporosis management

Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment

Clinical study of oral administration or intravenous injection of bisphosphonate for the treatment of postmenopausal osteoporosis

EFFECT OF XIAOYAO PILLS COMBINED WITH ALENDRONATE ON BONE DENSITY IN POSTMENOPAUSAL PATIENTS WITH OSTEOPOROSIS

Calcifediol (25-hydroxyvitamin D) improvement and calcium-phosphate metabolism of alendronate sodium/vitamin D3 combination in Chinese women with postmenopausal osteoporosis: a post hoc efficacy analysis and safety reappraisal

Post-pregnancy osteoporosis and its treatment